nCounter® PanCancer
Immune Profiling Panel

Helping Your Research

Perform multiplex gene expression analysis in human or mouse with 770 genes from different immune cell types, common checkpoint inhibitors, CT antigens, and genes covering both the adaptive and innate immune response. The panel measures many features of the immune response to facilitate rapid development of clinical actionable gene expression profiles in the context of cancer immunotherapy.

  • Comprehensive profiling of the immune response optimized for immuno-oncology research
  • Identify tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
  • Assess mechanistic pathway activity for single or combination studies
  • Customizable with up to 55 additional user-defined genes with Panel Plus option
Pancancer immune profiling product area


The nCounter PanCancer Immune Profiling Panel is for cancer researchers that need more markers than is practical for RT-qPCR but don’t want the broad approach that next-gen sequencing (NGS) offers. The Panel is fully compatible with clinically relevant sample types such as fresh-frozen (FF) tissue, formalin-fixed, paraffin-embedded (FFPE) tumor sections, isolated immune cell populations such as PBMCs, and cell lysates. The panel may be used in conjunction with nCounter Panel Plus products for additional flexibility in experimental design.

Panel Selection Tool

Find the gene expression panel for your research with easy to use panel pro

Find Your Panel

Product Information

Immune Cell Type Gene Coverage
Product Specifications
Product Comparison
Catalog Information
Immune Cell Type Gene Coverage
Product Specifications
Product Comparison

360 Series Product Comparison

Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.

Catalog Information

Related Resources

View All Related Resources
Whitepaper PanCancer Immune Profiling Advanced Analysis – Whitepaper
Product Bulletin Hallmarks of Cancer – Product Bulletin
Whitepaper Multiplexed Cancer Immune Response Analysis – Whitepaper


View All Publications

The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma.

Background: Tertiary lymphoid structures (TLSs) play key roles in tumour adaptive immunity. However, the prognostic value and molecular properties of TLSs in oesophageal squamous cell carcinoma (ESCC) patients have not been studied.

Location matters: LAG3 levels are lower in renal cell carcinoma metastatic sites compared to primary tumors, and expression at metastatic sites only may have prognostic importance.

While great strides have been made in the treatment of advanced renal cell carcinoma (RCC) with the emergence of immune checkpoint inhibitors (ICIs) and VEGFR-targeting drugs, sizable proportions of patients still do not respond to upfront therapy and long-term responses only occur in a minority of patients. There is therefore a great need for the development of better predictors of response and an increased understanding of mechanisms of resistance to these therapies.

The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis.

Brain metastases (BrMs) are a common occurrence in lung cancer with a dismal outcome. To understand the mechanism of metastasis to inform prognosis and treatment, here we analyze primary and metastasized tumor specimens from 44 non-small cell lung cancer patients by spatial RNA sequencing, affording a whole transcriptome map of metastasis resolved with morphological markers for the tumor core, tumor immune microenvironment (TIME), and tumor brain microenvironment (TBME).

Request a Quote

Contact our helpful experts and we’ll be in touch soon.